CN105982860B - Guaifenesin water-free swallowable taste-masking granule - Google Patents
Guaifenesin water-free swallowable taste-masking granule Download PDFInfo
- Publication number
- CN105982860B CN105982860B CN201510073328.0A CN201510073328A CN105982860B CN 105982860 B CN105982860 B CN 105982860B CN 201510073328 A CN201510073328 A CN 201510073328A CN 105982860 B CN105982860 B CN 105982860B
- Authority
- CN
- China
- Prior art keywords
- guaifenesin
- taste
- masking
- anhydrous
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Abstract
The invention provides a guaifenesin anhydrous swallow taste masking granule which is prepared by mixing a guaifenesin coated pellet and a taste-modifying material, wherein the guaifenesin coated pellet is prepared by coating a drug-loaded pellet with a specific taste masking layer and a specific smooth layer in sequence. The guaifenesin anhydrous swallowing taste masking particle covers the bitter taste and the peculiar smell of the medicine on one hand, and on the other hand, the guaifenesin anhydrous swallowing taste masking particle enables a patient to swallow the medicine without drinking water in the process of taking the medicine, thereby effectively improving the medication compliance; the granules are coated by the taste masking layer and the smooth layer, but the guaifenesin as the main drug can be quickly released and absorbed in vivo, the guaifenesin can be quickly released after being orally taken to the gastrointestinal system, and the coated taste masking layer and the smooth layer do not influence the release and absorption of the drug.
Description
Technical Field
The invention relates to a guaifenesin medicinal preparation, in particular to a guaifenesin anhydrous swallowing taste masking granule, which is orally taken by a patient without water for assisting pharynx smoothing, adopts an anhydrous swallowing mode for taking medicine, and belongs to the field of medicinal preparations.
Background
Guaifenesin is 3- (2-methoxyphenoxy) propane-1, 2-diol in the form of a white or off-white crystalline powder, sparingly soluble in water, soluble in ethanol.
After oral administration, the medicine stimulates gastric mucosa, and bronchial secretion is increased due to reflexivity, so that sputum is diluted. It also has disinfectant and antiseptic effects, and also has antitussive, spasmolytic, and anticonvulsive effects, and can be used for treating chronic bronchitis with symptoms of excessive phlegm cough, lung abscess, bronchiectasis, and secondary asthma. It is often combined with other antitussive and antiasthmatic herbs. Can be used for preventing mucus from expectoration.
The adverse reactions of the medicine are mainly nausea, dizziness, lethargy and allergy. It has effects of stimulating and dilating vascular smooth muscle, and is contraindicated for patients with pulmonary hemorrhage, acute gastroenteritis and nephritis.
In the prior art, guaifenesin pharmaceutical preparations are mainly syrup, granules and tablets, on one hand, bitter taste and peculiar smell exist after the guaifenesin pharmaceutical preparations are taken, so that the compliance of the medicaments after the medicaments are taken is influenced, on the other hand, when the existing guaifenesin oral solid preparations are taken, water needs to be drunk for smoothing the pharynx, and the application of the medicaments is limited for some patients who have inconvenience in drinking water.
At present, in the prior art, no research and report about granules which are swallowed without water or swallowed without water exist in oral solid preparations, particularly granules. Research and development of an oral solid preparation swallowed without water, in particular to an oral granule swallowed without water, not only expands the applicable patient population, but also greatly facilitates the patients to take medicine and the like, and has important inventive significance.
Disclosure of Invention
The invention aims to provide a novel guaifenesin medicinal preparation, in particular to guaifenesin water-free swallowing taste masking granules which not only effectively eliminate or mask the bitter taste and peculiar smell of a medicament, but also unexpectedly enable a patient to orally take the granules without drinking water to smooth the throat and take the granules in a water-free swallowing mode.
The technical scheme of the invention is as follows:
the invention provides a guaifenesin anhydrous swallow taste masking granule, which is formed by mixing a guaifenesin coating pellet and a taste-modifying material, and is characterized in that the guaifenesin coating pellet is prepared by coating a medicine-carrying pellet with a taste masking layer and a smooth layer in sequence, wherein: the taste masking layer is composed of an Ewing type E series and an optional plasticizer and/or an anti-sticking agent, the Ewing type E series is Ewing E100 or Ewing E PO, the plasticizer and/or the anti-sticking agent is selected from one or more of acetyl tributyl citrate, acetyl diethyl citrate, triethyl citrate, oleic acid, dibutyl sebacate, glycerol, propylene glycol, Tween-80, polyethylene glycol, talcum powder, glyceryl monostearate, magnesium stearate, titanium dioxide, calcium carbonate and magnesium oxide; the smooth layer is composed of a Eudragit E type series, sodium bicarbonate, carbomer 971PNF and optionally other auxiliary materials, wherein the Eudragit E type series is Eudragit E100 or Eudragit EPO, and the other auxiliary materials are one or more of glyceryl monostearate, magnesium stearate, stearic acid, titanium dioxide, talcum powder, calcium carbonate and magnesium oxide.
Preferably, the guaifenesin anhydrous swallow taste-masking granule, wherein the taste-masking layer consists of eucalyptus E100, talc, triethyl citrate and magnesium stearate.
Preferably, the guaifenesin anhydrous swallow taste-masking granule, wherein the smooth layer consists of eucalyptus E100, sodium bicarbonate, carbomer 971PNF, talc and stearic acid.
The guaifenesin anhydrous swallowing taste-masking granule is characterized in that the pill carrier is composed of guaifenesin and optionally a filler or an adhesive, and preferably the filler or the adhesive is one or more selected from microcrystalline cellulose, lactose, starch, pregelatinized starch, dextrin, glucose, mannitol, povidone, hypromellose, hyprolose and carbomer.
Preferably, the guaifenesin anhydrous swallow taste-masking granule, wherein the taste-masking layer accounts for 1.0-33.6% of the weight percentage of the guaifenesin coated pellets, and more preferably 5.0-23.6%.
Preferably, the guaifenesin anhydrous swallow taste-masking granule, wherein the smooth layer accounts for 0.5-40.7% of the weight percentage of the guaifenesin coated pellet, and more preferably 3.7-35.7%.
The guaifenesin anhydrous swallowing taste masking granule is characterized in that the taste masking material is composed of sorbitol and optionally existing auxiliary materials, the auxiliary materials are selected from a smoothing agent, essence, a sweetening agent or a flow aid, and preferably the auxiliary materials are selected from one or more of sodium carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, carbomer, xanthan gum, fruit essence, fresh milk essence, aspartame, sucralose, sodium cyclamate, acesulfame potassium, magnesium stearate or talcum powder.
Preferably, the guaifenesin anhydrous-swallowing taste-masking particle is prepared by mixing 0.5-10 parts by weight of guaifenesin anhydrous-swallowing taste-masking particles and 0.5-10 parts by weight of a flavoring material.
The guaifenesin anhydrous swallow taste-masking granule of the invention has the content of 0.5 to 31.8 percent of guaifenesin, and more preferably 2.0 to 21.8 percent.
As a specific embodiment of the present invention, the guaifenesin anhydrous swallow taste-masking granule comprises the following components in a unit preparation:
carrying pills: 100mg of guaifenesin, 10596.15mg of microcrystalline cellulose and K258.0mg of povidone;
taste masking layer: etex E10012.10mg, talcum powder 22.10mg, triethyl citrate 1.0mg and magnesium stearate 1.4 mg;
a smooth layer: eyqiz E1009.0mg, carbomer 971PNF 7.2mg, sodium bicarbonate 7.2mg, talcum powder 3.7mg and stearic acid 501.8 mg;
flavoring materials: sorbitol 549mg, sodium carboxymethylcellulose 10.0mg, orange essence 10.0mg, strawberry essence 8.0mg, aspartame 2.0mg and magnesium stearate 3.0 mg.
The Eudragit E100 is a methacrylic acid aminoalkyl ester copolymer E type (a copolymer of butyl methacrylate, dimethylaminoethyl methacrylate and methyl methacrylate (1:2: 1)), is colorless transparent or light yellow particles, has weak ammonia odor, and is commercially available from Wogongdegusai.
The carbomer 971PNF is a high-molecular polymer of acrylic acid bonded allyl sucrose or pentaerythritol allyl ether, and is white loose powder; has slightly sour taste and hygroscopicity, and is commercially available from Lubrizol.
The stearic acid 50 is a solid fatty acid obtained from animal or vegetable fat, mainly comprises stearic acid (C18H36O2) and palmitic acid (C16H32O2), is white or off-white powder or crystalline hard block with smooth feeling, and has fine needle-like crystals with slightly gloss on the section; has slight odor like grease and no odor. The product is soluble in chloroform or diethyl ether, soluble in ethanol, and insoluble in water. The commercial source is BASF.
The povidone K25 is a nonionic polymer compound, which is a linear homopolymer synthesized from polyvinylpyrrolidone and 1-ethylene-2-pyrrolidone, and the commercial source is ISP.
The microcrystalline cellulose 105 of the present invention is a uniform polymer formed by connecting D-glucopyranosyl groups with 1,4- β -glycosidic bonds, and the product is widely used in oral pharmaceutical preparations and foods, is relatively nontoxic and non-irritant, is not absorbed after oral administration, and has almost no potential toxicity.
The guaifenesin anhydrous swallowing taste masking particle disclosed by the invention adopts a preparation form that a main drug and a specific auxiliary material are used for preparing a drug-carrying particle or a pellet, and then a specific high polymer material is adopted for sequentially carrying out coating of a taste masking functional film coat and coating of a smooth layer, so that a part of specific taste-modifying material is mixed outside the obtained coated pellet, and the prepared guaifenesin anhydrous swallowing taste masking particle covers the bitter taste and the peculiar smell of a drug on one hand, and on the other hand, the guaifenesin anhydrous swallowing taste masking particle is unexpected, so that a patient can swallow without drinking water in the taking process, the patient does not have bad taste and bitter taste in the taking process, and the drug compliance is effectively improved; improves the applicable population of patients, and is particularly beneficial to administration of the medicine to children. And test results also prove that although the granules are coated by the taste-masking layer and the smooth layer, the guaifenesin serving as the main drug can be quickly released and absorbed in vivo and can be quickly released after being orally taken to a gastrointestinal system, and the coated taste-masking layer and the smooth layer do not influence the release and absorption of the drug.
Drawings
FIG. 1: example 1 Release of guaifenesin Anhydrous swallowable taste-masking particles in 0.01mol/L HCl vehicle
FIG. 2: test for investigating influence of taste masking layer weight gain on release degree
FIG. 3: test for investigating influence of weight gain of smooth layer on release degree
Detailed Description
The following examples are intended to illustrate or explain the technical solution of the present invention, and do not limit the scope of the patent.
Example 1: guaifenesin water-free swallowable taste-masking granule
The guaifenesin anhydrous swallowed taste-masking granule unit preparation consists of the following components:
form a list:
the preparation process comprises the following steps:
the preparation method of the drug-loaded pill comprises extruding and rounding, coating a taste-masking layer and a smooth layer on the drug-loaded pill, respectively, coating each layer with fluidized bed, and mixing the coated pellet with taste-modifying material to obtain semi-finished product. The preparation process comprises the following steps:
1. preparing the pill:
the drug-loaded pill is prepared by adopting an extrusion rounding mode.
1.1 preparation of adhesive: povidone K25 in the prescribed amount was formulated into a 15% (w/w) aqueous solution for use.
1.2 preparing soft materials: placing the microcrystalline cellulose 105 and guaifenesin in a prescription amount in a wet granulation granulator, starting the granulator to stir uniformly, adding the adhesive solution in a pouring manner when the materials are stirred, adding a proper amount of purified water when the granulator is in an operating state after the materials are added, and continuously stirring for a certain time to obtain the soft material.
1.3 Soft material extrusion: extruding the material by using an extruding screen with the diameter of 0.5mm to obtain an extrudate with proper length.
1.4 shot blasting: and adding an extrudate into the shot blasting machine in an operating state, throwing the pellets by the rotating speed of the shot blasting machine according to the principle of slow first and fast second, and operating for a certain time to prepare the required pellets.
1.5, drying: drying the pellets by adopting a fluidized bed, controlling the temperature of the material to be 40 ℃, controlling the moisture of the pellets to be 2-4%, and collecting the pellets of 35-50 meshes.
2. Coating of taste-masking layer
2.1 preparation of taste masking layer solution:
mixing appropriate amount of ethanol and water to obtain ethanol water solvent, dissolving Ewing E100 in the above 50% solvent, dispersing the rest 50% solvent in the rest part of the prescription, adding the dispersion into the stirred Ewing solution, and stirring for 20min to obtain the final solution.
2.2 coating of taste-masking layer:
coating the taste-masking layer by using a fluidized bed, wherein the material is controlled to be 30 +/-5 ℃ in the coating process.
3. And (3) coating a smooth layer:
3.1 preparation of smooth layer solution:
dissolving Ewing E100 in 50% ethanol, adding the rest components of the formula into the rest 50% ethanol to form colloidal suspension, adding the colloidal suspension into the stirred Ewing E100 solution, and homogenizing with homogenizer for 45min to obtain the final solution.
3.2, coating of the smooth layer:
coating the taste-masking layer by using a fluidized bed, and controlling the temperature of the material to be 30 +/-5 ℃ in the coating process according to the properties of the material.
4. Mixing flavoring materials:
mixing the coated pellet with taste-modifying material to obtain the guaifenesin anhydrous swallow taste-masking granule.
Evaluation of the effect of the preparation: dissolution rate, mouthfeel and no water swallowing effect. The results are shown in the following table.
Table 1 release in water is shown below
In order to simulate the drug release rate of the drug in the oral cavity, the release degree in water is detected to evaluate the taste masking effect of the drug in the oral cavity, the result shows that the 5min release degree of the drug in water is 2.7%, the drug is hardly released, and 10 volunteers with good health states are searched for testing the drug, so that the drug does not taste bitter or peculiar smell within 5min of the oral cavity, and the cool and fast feeling in the oral cavity is reflected after the drug is taken, thereby the effect of masking the bad taste of the drug is achieved.
The effect of water-free swallowing: the blank coated pellets are mixed to prepare a final preparation, after oral administration by volunteers, 90% of the volunteers can swallow smoothly within 1min under the state of no water and smooth throat, and the other 10% of the volunteers finish swallowing administration within 1.5 min.
TABLE 2 Release in 0.01mol/L HCl
The results show that: the medicine can release medicine rapidly in acid, and meet the requirement of rapid onset after oral administration.
Example 2: guaifenesin water-free swallowable taste-masking granule
1. The prescription composition and preparation process parameters of the pill loading are as follows:
2. preparation and coating process of taste-masking layer solution
3. Preparation and packaging process of smooth layer solution
4. The influence of each layer weight gain on the release degree is investigated:
test for investigating influence of taste-masking layer weight gain on release degree: the results are shown in tables 3 to 4 below and FIG. 2
1.1 degree of release in water: the results are shown in Table 3.
TABLE 3 degree of Release in Water
The results show that: the samples with 7.3% weight of the taste masking layer are released in water beyond the limit requirement due to the thin coating, and other samples with weight gain meet the limit requirement.
1.2 degree of release in acid: the results are shown in Table 4 and FIG. 2.
TABLE 4 degree of release in acid
And (4) analyzing results: the taste masking layer had no effect on the release in the range considered.
(II) the effect of the weight gain of the smooth layer on the release degree is investigated and tested: the results are shown in Table 5 and FIG. 3
1.3 release degree of the smooth layer pellet in acid: the results are shown in Table 5 and FIG. 3.
TABLE 5 Effect of smooth layer weight gain on Release
The results show that: within the range investigated, the smooth layer weight gain had no significant effect on the degree of release in acid.
Claims (14)
1. The guaifenesin anhydrous swallow taste masking granule is formed by mixing a guaifenesin coating pellet and a taste modifying material, and is characterized in that the guaifenesin coating pellet is prepared by coating a medicine carrying pellet with a taste masking layer and a smooth layer in sequence, wherein:
the taste masking layer is composed of an Ewing type E series and an optional plasticizer and/or an anti-sticking agent, the Ewing type E series is Ewing E100 or Ewing E PO, the plasticizer and/or the anti-sticking agent is selected from one or more of acetyl tributyl citrate, acetyl diethyl citrate, triethyl citrate, oleic acid, dibutyl sebacate, glycerol, propylene glycol, Tween-80, polyethylene glycol, talcum powder, glyceryl monostearate, magnesium stearate, titanium dioxide, calcium carbonate and magnesium oxide; the smooth layer is composed of a Eudragit E type series, sodium bicarbonate, carbomer 971PNF and optionally other auxiliary materials, wherein the Eudragit E type series is Eudragit E100 or Eudragit E PO, and the other auxiliary materials are selected from one or more of glyceryl monostearate, magnesium stearate, stearic acid, titanium dioxide, talcum powder, calcium carbonate and magnesium oxide;
the flavoring material is composed of sorbitol and optional auxiliary materials, the auxiliary materials are selected from a smoothing agent, essence, a sweetening agent and a flow aid, and the smoothing agent is selected from one or more of sodium carboxymethylcellulose, hypromellose, hyprolose, carbomer and xanthan gum.
2. The guaifenesin anhydrous swallow taste-masking granule as claimed in claim 1, wherein said taste-masking layer is comprised of Ewing E100, talc, triethyl citrate and magnesium stearate.
3. The guaifenesin anhydrous swallow taste masked granule according to claim 1 wherein the smooth layer is comprised of eucalyptus E100, sodium bicarbonate, carbomer 971PNF, talc and stearic acid.
4. The guaifenesin anhydrous, swallowable, taste-masking granule according to claim 1, wherein the pill carrier is comprised of guaifenesin and optionally a filler or binder.
5. The guaifenesin anhydrous-swallow taste-masked granule according to claim 4, wherein in the carrier pill, the filler or binder is selected from one or more of microcrystalline cellulose, lactose, starch, pregelatinized starch, dextrin, glucose, mannitol, povidone, hypromellose, hyprolose, and carbomer.
6. The guaifenesin anhydrous swallow taste-masking granule as claimed in claim 1, wherein said taste-masking layer is 1.0-33.6% by weight of the guaifenesin coated pellet.
7. The guaifenesin anhydrous swallow taste-masking granule as claimed in claim 6, wherein said taste-masking layer is 5.0-23.6% by weight of the guaifenesin coated pellet.
8. The guaifenesin anhydrous swallow taste-masking granule as claimed in claim 1, wherein said smooth layer is 0.5-40.7% by weight of the guaifenesin coated pellet.
9. The guaifenesin anhydrous swallow taste-masked granule according to claim 8, wherein the smooth layer is 3.7-35.7% by weight of the coated guaifenesin pellet.
10. The guaifenesin anhydrous swallow taste-masking granule as claimed in claim 1, wherein in the taste-masking material, the auxiliary material contains one or more of a smoothing agent selected from sodium carboxymethylcellulose, hypromellose, hyprolose, carbomer and xanthan gum; the essence is selected from one or more of fruit essence and fresh milk essence; the sweetener is one or more selected from aspartame, sucralose, sodium cyclamate and acesulfame potassium; the glidant is selected from one or more of magnesium stearate and talcum powder.
11. The guaifenesin anhydrous-swallow taste-masking granule according to claim 1, wherein the guaifenesin anhydrous-swallow taste-masking granule is prepared by mixing 0.5 to 10 parts by weight of a guaifenesin coated pellet and 0.5 to 10 parts by weight of a flavoring material.
12. The guaifenesin anhydrous swallow taste-masking granule according to claim 1, wherein the guaifenesin content is from 0.5% to 31.8%.
13. The guaifenesin anhydrous swallow taste-masking granule according to claim 12, wherein the guaifenesin content is from 2.0% to 21.8%.
14. The guaifenesin anhydrous swallow taste-masking granule according to any one of claims 1 to 9, wherein the unit formulation comprises the following components:
(1) carrying pills: 100mg of guaifenesin, 10596.15mg of microcrystalline cellulose and K258.0mg of povidone;
(2) taste masking layer: etex E10012.10mg, talcum powder 22.10mg, triethyl citrate 1.0mg and magnesium stearate 1.4 mg;
(3) a smooth layer: eyqiz E1009.0mg, carbomer 971PNF 7.2mg, sodium bicarbonate 7.2mg, talcum powder 3.7mg and stearic acid 501.8 mg;
(4) flavoring materials: sorbitol 549mg, sodium carboxymethylcellulose 10.0mg, orange essence 10.0mg, strawberry essence 8.0mg, aspartame 2.0mg and magnesium stearate 3.0 mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510073328.0A CN105982860B (en) | 2015-02-11 | 2015-02-11 | Guaifenesin water-free swallowable taste-masking granule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510073328.0A CN105982860B (en) | 2015-02-11 | 2015-02-11 | Guaifenesin water-free swallowable taste-masking granule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105982860A CN105982860A (en) | 2016-10-05 |
| CN105982860B true CN105982860B (en) | 2020-04-14 |
Family
ID=57041310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510073328.0A Active CN105982860B (en) | 2015-02-11 | 2015-02-11 | Guaifenesin water-free swallowable taste-masking granule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105982860B (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000336026A (en) * | 1999-05-26 | 2000-12-05 | Lion Corp | Granulated composition and tablet |
| MXPA04010225A (en) * | 2002-04-15 | 2005-07-05 | Adams Lab Inc | Sustained release of guaifenesin combination drugs. |
| WO2004022037A1 (en) * | 2002-09-04 | 2004-03-18 | Ranbaxy Laboratories Limited | Taste masked dosage forms and processes for their preparation |
| US20050095288A1 (en) * | 2003-11-03 | 2005-05-05 | Andrx Labs, Llc | Decongestant and expectorant tablets |
| CN1994285B (en) * | 2006-01-04 | 2011-03-16 | 上海医药工业研究院 | Sustained release micro-pellet of guaifenesin and preparation process thereof |
| EP2144599B1 (en) * | 2007-03-02 | 2010-08-04 | Farnam Companies, Inc. | Sustained release pellets comprising wax-like material |
| CN102000344B (en) * | 2010-07-16 | 2013-06-12 | 钟术光 | Medicament coating composition with masked taste |
-
2015
- 2015-02-11 CN CN201510073328.0A patent/CN105982860B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105982860A (en) | 2016-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2237121T3 (en) | FAST DISGREGABLE SOLID PREPARATION. | |
| JP5053865B2 (en) | Method for producing orally disintegrating solid preparation | |
| ES2398564T3 (en) | Gastro-resistant pharmaceutical formulations containing rifaximin | |
| JP5128948B2 (en) | Novel pharmaceutical composition for the treatment of cancer | |
| TWI324928B (en) | Pharmaceutical composition for the treatment of cancer | |
| EP1194153B1 (en) | Taste masked pharmaceutical liquid formulations | |
| JP5237098B2 (en) | Orally disintegrating tablet masking bitterness and method for producing the same | |
| CN101636152B (en) | Controlled-release preparation containing cilostazol and process for the preparation thereof | |
| EP2246052B1 (en) | Orally rapidly disintegrating tablet comprising imidafenacin | |
| CN113262208B (en) | Azithromycin taste-masking dry suspension granule and preparation method thereof | |
| WO2011110939A2 (en) | Pharmaceutical compositions of substituted benzhydrylpiperazines | |
| WO2001072285A1 (en) | Easy-to-take granule | |
| WO2012147660A1 (en) | Rapidly dissolving oral tablet | |
| CN109996542A (en) | Oral disnitegration tablet comprising diamine derivative | |
| WO2016051782A1 (en) | Oral preparation in which bitter taste of bitter-tasting drug is masked | |
| CN105982861B (en) | Azithromycin water-free swallow taste-masking granule | |
| JP2008174511A (en) | Bitter taste-masking composition | |
| CN105982860B (en) | Guaifenesin water-free swallowable taste-masking granule | |
| CN107625734B (en) | Water-free swallow taste masking preparation and preparation method thereof | |
| CN108113971B (en) | Ambroxol hydrochloride taste masking preparation and preparation method thereof | |
| CN107625733B (en) | Clarithromycin granules capable of being swallowed without water and preparation method thereof | |
| JP2005139086A (en) | Quick-disintegration preparation | |
| CN114948969B (en) | Pharmaceutical composition comprising a crystalline form of a compound and fumaric acid, process for the preparation thereof and use thereof | |
| JP6692549B2 (en) | Pediatric formulation containing bile acids | |
| JP6600084B2 (en) | Tablets containing tosufloxacin tosylate, disintegrant and acidic amino acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |